November 15, 2024 8:00am

Can they also hear the oversold screaming for attention?

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!

MY Pre-Open Thoughts: 3 Positive and 3 Negative Indications

Never leave an investor uninform

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

 

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!

 

RegMed Investors (RMi) Closing Bell: further erosion … https://www.regmedinvestors.com/articles/13698

RegMed Investors (RMi) Research Note: Q3/24 earnings reporting dates, net losses, cash positions, revenue and runway outcomes … https://www.regmedinvestors.com/articles/13441

RegMed Investors (RMi) - Q3/24 Cell and Gene Therapy Earnings Scorecard Results … https://www.regmedinvestors.com/articles/11628

 

Friday: The pre-open Dow futures are Down -0.37% (-163 points), the S&P futures are DOWN -0.53% or (-31 points) and the Nasdaq futures are DOWN -0.79% or (-165 points)

  • U.S. stock futures fell on Friday, November 15, 2024
  • European markets were lower,
  • Asia Pacific markets were mixed

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

  • Thursday: The Dow closed DOWN -207.58 points or -0.47%, the S&P closed DOWN -36.20 points or -0.60% while the Nasdaq closed DOWN -123.07 points or -0.64%
  • The 3 major indexes are tracking to end the week lower, giving up some gains seen during last week’s climb on the back of X-president Trump’s victory in the presidential election. The Nasdaq has dropped -0.9% this week, the S&P 500 -$0.08% and the Dow- 0.5%.

Economic Data Docket: Retail sales, month-over-month, October (+0.3% expected, +0.4% previously); Retail sales ex-auto and gas, October (+0.3% expected, +0.7% previously); Import price index, month-over-month, October (-0.1% expected, -0.4% prior); Industrial production month-over-month, October (-0.2% expected, -0.3% prior)

 

Q4/24: November 6 negative and 4 positive closes

  • October: 8 positive and 15 negative closes

Q3/24:

  • September – 10 positive and 10 negative close
  • August – I neutral, 10 positive and 11 negative closes
  • July: 1 market holiday. 1 day off, 6 negative, 1 neutral and 12 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context 

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.

A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Positive Indications:

Thursday, Wednesday, Tuesday, Monday, Friday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)  

Blueprint Medicine (BPMC) closed down -$1.23 after Wednesday’s +$0.26, Tuesday’s -$3.25 and Monday’s -$0.96 with a positive +$0.85 or +0.89% pre-open.

CRISPR Therapeutics (CRSP) closed down -$2.94 after Wednesday’s -$0.94, Tuesday’s -$4.13 and Monday’s +$3.24 with a positive +$0.18 or +0.38% pre-open

Intellia Therapeutics (NTLA) closed down -$0.99 after Wednesday’s -$0.54, Tuesday’s -$0.85 and Monday’s +$0.77 with a positive +$0.01 or +0.07% pre-open

 

Negative Indication:

Thursday, Wednesday, Tuesday, Monday, Friday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)  

Beam Therapeutics (BEAM) closed down -$0.31 after Wednesday’s -$0.44, Tuesday’s -$2.41, Monday’s +$3.29, and last Friday’s +$0.96 with a negative -$0.31 or -1.18% aftermarket

Ultragenyx Pharmaceuticals (RARE) closed down -$1.07 after Wednesday’s +$0.87 and Tuesday’s -$2.89 with a negative -$0.64 or -1.34% aftermarket

Mesoblast (MESO) closed down -$0.39 after Wednesday’s +$1.76 after Tuesday’s +$0.22 after Monday’s +$0.55 with a negative -$0.72 or -6.36% aftermarket

 

The BOTTOM LINE: TGIF, after a bad reaction to COVID shot ... like my market week!

 

Ranking the end of October:     

  • 11/14 – Thursday: closed negative with 3 incliner, 31 decliners and 1 flat
  • 11/13 – Wednesday: closed negative with 8 incliner, 25 decliners and 2 flats
  • 11/12 – Tuesday: closed negative with 7 incliner, 27 decliners and 1 flat
  • 11/11 – Monday closed positive with 23 incliner, 11 decliners and 1 flat
  • 11/8 – Friday: closed negative with 15 incliner, 18 decliners and 2 flats
  • 11/7 – Thursday: closed negative with 11 incliner, 20 decliners and 4 flats
  • 11/6 – Wednesday: closed positive with 26 incliner, 7 decliners and 2 flats
  • 11/5 – Tuesday closed positive with 25 incliner, 8 decliners and 2 flats
  • 11/4 – Monday closed negative with 15 incliner, 18 decliners and 2 flats
  • 11/1 - Friday advance/decline line closed positive with 26 incliner, 7 decliners and 2 flats

 

Welcome to my world of defining the “grey’ in our universe!

  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.